Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of “Hold” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus rating of “Hold” from the six analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $52.00.

Several research analysts recently issued reports on the company. Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Benchmark restated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America restated a “neutral” rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, Wells Fargo & Company lifted their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th.

Omnicell Trading Down 1.5 %

OMCL stock opened at $46.90 on Wednesday. The firm has a 50 day moving average of $44.70 and a 200-day moving average of $38.28. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -120.25, a PEG ratio of 36.17 and a beta of 0.77.

Hedge Funds Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after buying an additional 508,789 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after buying an additional 3,570 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after purchasing an additional 243,353 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.